Skip to content

The efficacy and safety of Oselidine in laparoscopic cholecystectomy.

The efficacy and safety of Oselidine in laparoscopic cholecystectomy.

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500105889
Enrollment
Unknown
Registered
2025-07-14
Start date
2025-07-09
Completion date
Unknown
Last updated
2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative nausea and vomiting

Interventions

Oliceridine group:The induction dose of the oliceridine group was 0.1mg/kg. Intraoperative anesthesia maintenance: Propofol (4-6 mg/kg/h), remifentanil (0.2-0.5 µg/kg/min), sevoflurane (0-2%/L/min).
Sufentanil group:The anesthesia induction dose in the sufentanil group was 0.5 µg/kg. Intraoperative anesthesia maintenance: propofol (4-6 mg/kg/h), remifentanil (0.2-0.5 µg/kg/min), sevoflurane (0-2%

Sponsors

Qiandongnan Prefecture People's Hospital, Kaili City, Guizhou Province
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) Patients aged 18 to 65 years old, regardless of gender; (2) The body massindex (BMI) is 18-30 kg/m^2; (3) The classification of the American Society of Anesthesiologists (ASA) is grade ?-?; (4) Laparoscopic cholecystectomy under general anesthesia; (5) The subjects voluntarily participated and signed the informed consent form.

Exclusion criteria

Exclusion criteria: (1) Patients with contraindications to general anesthesia; (2) Those who are allergic to or contraindicated to the drugs (such as opioids) or their components used in the study; (3) Patients with a history of craniocerebral injury, cerebrovascular accident, or suffering from central nervous system diseases and mental system diseases; (4) Patients who have been using psychotropic drugs, anesthetic analgesics, sedative-hypnotic drugs or non-steroidal anti-inflammatory drugs for a long time; (5) Patients diagnosed with difficult airways; (6) Participated in other clinical trials as a subject within 3 months prior to inclusion.

Design outcomes

Primary

MeasureTime frame
Postoperative nausea and vomiting;

Secondary

MeasureTime frame
Time of Postoperative Extubation;15-item recovery quality scale 24 hours after operation;

Countries

China

Contacts

Public ContactPan Qin

Qiandongnan Prefecture People's Hospital, Kaili City, Guizhou Province

895184393@qq.com+86 182 8550 0103

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026